Search Results

The product title you are looking for is no longer available. Other similar products that may interest you are listed below:

Refine your Search

Results for 'CLL PHARMA -Company Report'
Title Publication Date Price Relevance
CLL PHARMA-Therapeutic Competitors Report Mar 2011 £220 100%
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review
H2 2011
 Oct 2011 £315 90%
Leukemia Therapeutics Market (2010-2020)
(Acute/Chronic Lymphocytic Leukemia & Acute/Chronic Myeloid Leukemia) Pipeline Forecast & Market Forecast in G8 Countries
 Nov 2011 £4,110 67%
BTG plc – Product Pipeline Review
H2 2011
 Nov 2011 £315 67%
Medicine (Pharmaceutical Drug): Analysis of French Companies Aug 2011 £495 66%
Pharmaceutical Manufacturers: Analysis of French Companies Aug 2011 £495 66%
Pharmaceuticals:Analysis of French Companies Aug 2011 £495 64%
Anti-CD20 Monoclonal Antibodies Jul 2010 £2,500 62%
Competitive Outlook on Lung Cancer Drug Development
The Missing Handbook to New Product Planning and Portfolio Planning
 Aug 2009 £2,035 61%
Pipeline Insight: Biologic Targeted Cancer Therapies
Next generation jostles for market position
 Dec 2009 £7,210 58%
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market Jul 2011 £1,620 57%
Leukemia
A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking
 Apr 2009 £1,620 57%
CNS Therapeutics May 2008 £2,500 56%
Competitive Outlook on Apoptosis in Oncology Dec 2006 £1,620 55%
Cyclacel Pharmaceuticals Inc. – Product Pipeline Review
H2 2011
 Nov 2011 £315 54%
Pipeline Insight: Small Molecule Targeted Cancer Therapies
New targets set to drive growth
 Apr 2010 £7,210 53%
ASCO 2009: Significant Developments in Context Jul 2009 £595 52%
Targeted Therapies in Oncology
A World Review
 Dec 2006 £4,110 46%
Polymerase Chain Reaction (PCR) – Products/Tools
A Global Market Watch, 2009-2015
 Nov 2011 £2,180 38%
New Drug Futures 2009 Jan 2012 £1,995 38%
Polymerase Chain Reaction (PCR) In Medical Application
An Analytical Report, 2009-2015
 Nov 2011 £3,550 33%